<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00567060</url>
  </required_header>
  <id_info>
    <org_study_id>N01001</org_study_id>
    <nct_id>NCT00567060</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Piracetam Taken for 12 Months in Subjects Suffering From Mild Cognitive Impairment (MCI)</brief_title>
  <official_title>A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of 9600 and 4800 mg/Day Piracetam Taken for 12 Months by Subjects Suffering From Mild Cognitive Impairment (MCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to explore in a more documented way the relative potential and
      efficacy of piracetam 9600 and 4800 mg daily.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <completion_date type="Actual">January 2004</completion_date>
  <primary_completion_date type="Actual">January 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive Battery Composite Score over a 52-week period</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety of piracetam for 12 months</measure>
  </secondary_outcome>
  <enrollment type="Actual">676</enrollment>
  <condition>Memory Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piracetam</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male/female between 50 and 89 years (inclusive)

          -  declining cognitive function of at least 3 months duration interfering with complex
             activities of daily living

          -  normal basic activities of daily independent living

          -  Clinical Dementia Rating scale score equal to 0.5

          -  score at least one point above the lowest possible score on 7 out of 8 tests in the
             cognitive battery at both Selection Visit and Baseline Visit

        Exclusion Criteria:

          -  general anesthetics within 3 months of selection visit

          -  history of severe allergic drug reaction(s)

          -  history of drug or alcohol dependence (DSM IV defined) within the last 12 months

          -  any drug prescribed to activate cerebral metabolism, taken within 1 week of screening
             or/and concomitantly

          -  concomitant intake of anticoagulent medications

          -  concomitant intake or intake within 1 week before screening of drug that might affect
             cognitive function or central nervous system

          -  history of dementia, psychiatric or neurological disorders, mental retardation,
             learning disabilities and stroke

          -  current depression

          -  impaired renal function, thyroid function or neurological degeneration

          -  any gastrointestinal dysfunction that might interfere with the absorption or
             elimination of the study drug

          -  insulin-dependant diabetes mellitus

          -  bleeding disorders or disturbance in hemostatic function.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>UCB Pharma</affiliation>
  </overall_official>
  <link>
    <url>http://www.ucb.com/_up/ucb_com_patients/documents/N01001_CSS_20070907.pdf</url>
    <description>Clinical Study Summary on UCB.com</description>
  </link>
  <results_reference>
    <citation>Jelic V, Kivipelto M, Winblad B. Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):429-38. Epub 2005 Nov 23. Review. Erratum in: J Neurol Neurosurg Psychiatry. 2006 Jul;77(7):892.</citation>
    <PMID>16306154</PMID>
  </results_reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2007</study_first_submitted>
  <study_first_submitted_qc>November 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2007</study_first_posted>
  <last_update_submitted>December 13, 2013</last_update_submitted>
  <last_update_submitted_qc>December 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2013</last_update_posted>
  <keyword>Piracetam</keyword>
  <keyword>Nootropil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Memory Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

